Brendan J Guercio1,2, Nancy J Donovan1,2,3,4, Catherine E Munro5, Sarah L Aghjayan2,3,5, Sarah E Wigman3,5, Joseph J Locascio5, Rebecca E Amariglio1,2,3,4,5, Dorene M Rentz1,2,3,4,5, Keith A Johnson1,2,3,6, Reisa A Sperling1,2,3,5, Gad A Marshall1,2,3,5. 1. Harvard Medical School, Boston, MA, USA. 2. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, MA, USA. 3. Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA. 4. Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA. 5. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. 6. Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Apathy is a common neuropsychiatric symptom in Alzheimer's disease (AD) dementia and mild cognitive impairment (MCI). Detecting apathy accurately may facilitate earlier diagnosis of AD. The Apathy Evaluation Scale (AES) is a promising tool for measurement of apathy in prodromal and possibly preclinical AD. OBJECTIVE: To compare the three AES sub-scales - subject-reported (AES-S), informant-reported (AES-I), and clinician-reported (AES-C) - over time in individuals at risk for AD due to MCI and advanced age (cognitively normal [CN] elderly). METHODS: Mixed effects longitudinal models were used to assess predictors of score for each AES sub-scale. Cox proportional hazards models were used to assess which AES sub-scales predict progression from MCI to AD dementia. RESULTS: Fifty-seven MCI and 18 CN subjects (ages 53-86) were followed for 1.4 ± 1.2 years and 0.7 ± 0.7 years, respectively. Across the three mixed effects longitudinal models, the common findings were associations between greater apathy and greater years in study, a baseline diagnosis of MCI (compared to CN), and male gender. CN elderly self-reported greater apathy compared to that reported by informants and clinicians, while individuals with MCI under-reported their apathy compared to informants and clinicians. Of the three sub-scales, the AES-C best predicted transition from MCI to AD dementia. CONCLUSION: In a sample of CN elderly and elderly with MCI, apathy increased over time, particularly in men and those with MCI. AES-S scores may be more sensitive than AES-I and AES-C scores in CN elderly, but less reliable if subjects have MCI. Moreover, the AES-C sub-scale predicted progression from MCI to AD dementia.
BACKGROUND: Apathy is a common neuropsychiatric symptom in Alzheimer's disease (AD) dementia and mild cognitive impairment (MCI). Detecting apathy accurately may facilitate earlier diagnosis of AD. The Apathy Evaluation Scale (AES) is a promising tool for measurement of apathy in prodromal and possibly preclinical AD. OBJECTIVE: To compare the three AES sub-scales - subject-reported (AES-S), informant-reported (AES-I), and clinician-reported (AES-C) - over time in individuals at risk for AD due to MCI and advanced age (cognitively normal [CN] elderly). METHODS: Mixed effects longitudinal models were used to assess predictors of score for each AES sub-scale. Cox proportional hazards models were used to assess which AES sub-scales predict progression from MCI to AD dementia. RESULTS: Fifty-seven MCI and 18 CN subjects (ages 53-86) were followed for 1.4 ± 1.2 years and 0.7 ± 0.7 years, respectively. Across the three mixed effects longitudinal models, the common findings were associations between greater apathy and greater years in study, a baseline diagnosis of MCI (compared to CN), and male gender. CN elderly self-reported greater apathy compared to that reported by informants and clinicians, while individuals with MCI under-reported their apathy compared to informants and clinicians. Of the three sub-scales, the AES-C best predicted transition from MCI to AD dementia. CONCLUSION: In a sample of CN elderly and elderly with MCI, apathy increased over time, particularly in men and those with MCI. AES-S scores may be more sensitive than AES-I and AES-C scores in CN elderly, but less reliable if subjects have MCI. Moreover, the AES-C sub-scale predicted progression from MCI to AD dementia.
Authors: S M Albert; K Michaels; M Padilla; G Pelton; K Bell; K Marder; Y Stern; D P Devanand Journal: Am J Geriatr Psychiatry Date: 1999 Impact factor: 4.105
Authors: A J Saykin; H A Wishart; L A Rabin; R B Santulli; L A Flashman; J D West; T L McHugh; A C Mamourian Journal: Neurology Date: 2006-09-12 Impact factor: 9.910
Authors: Jennifer R Gatchel; Nancy J Donovan; Joseph J Locascio; J Alex Becker; Dorene M Rentz; Reisa A Sperling; Keith A Johnson; Gad A Marshall Journal: Am J Geriatr Psychiatry Date: 2017-01-04 Impact factor: 4.105
Authors: Gad A Marshall; Jennifer R Gatchel; Nancy J Donovan; Martha C Muniz; Aaron P Schultz; J Alex Becker; Jasmeer P Chhatwal; Bernard J Hanseeuw; Kathryn V Papp; Rebecca E Amariglio; Dorene M Rentz; Reisa A Sperling; Keith A Johnson Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Jacob N Miller; Alison Kruger; David J Moser; Laurie Gutmann; Ellen van der Plas; Timothy R Koscik; Sarah A Cumming; Darren G Monckton; Peggy C Nopoulos Journal: Front Neurol Date: 2021-07-01 Impact factor: 4.003